Search

Your search keyword '"Munakata, Wataru"' showing total 20 results
Start Over Author "Munakata, Wataru" Journal international journal of hematology
20 results on '"Munakata, Wataru"'

4. Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies

Author

Munakata, Wataru, primary, Ando, Kiyoshi, additional, Yokoyama, Masahiro, additional, Fukuhara, Noriko, additional, Yamamoto, Kazuhito, additional, Fukuhara, Suguru, additional, Ohmachi, Ken, additional, Mishima, Yuko, additional, Ichikawa, Satoshi, additional, Ogiya, Daisuke, additional, Aoi, Arata, additional, Hatsumichi, Masahiro, additional, and Tobinai, Kensei, additional

Published
2022
Full Text
View/download PDF

14. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL

Author

Maruyama, Dai, Watanabe, Takashi, Maeshima, Akiko Miyagi, Nomoto, Junko, Taniguchi, Hirokazu, Azuma, Teruhisa, Mori, Masakazu, Munakata, Wataru, Kim, Sung-Won, Kobayashi, Yukio, Matsuno, Yoshihiro, and Tobinai, Kensei

Published
2010
Full Text
View/download PDF

18. CD3+ CD56+ EBER1+ atypical extraosseous plasmacytoma of the nasal cavity.

Author

Ando, Yayoi, Maeshima, Akiko Miyagi, Fukuhara, Suguru, Makita, Shinichi, Munakata, Wataru, Suzuki, Tatsuya, Maruyama, Dai, Taniguchi, Hirokazu, and Izutsu, Koji

Abstract

We present a case of atypical extraosseous plasmacytoma (EP) with a plasmablastic morphology and CD3+ CD56+ Epstein-Barr virus-encoded RNA-1 (EBER1)+ phenotypes of the nasal cavity. A 51-year-old male attended a local hospital with a tumor located in his left nasal cavity that was histologically diagnosed as extranodal NK/T cell lymphoma, nasal type. We reviewed the specimens and re-biopsied the tumor, and confirmed that the tumor was positive for CD3, CD56, and EBER1; however, the tumor showed a plasmablastic morphology without necrosis and angiocentricity, and was positive for CD138, but negative for CD20 and PAX5. Given a plasmablastic morphology and EBER1 positivity, but a relatively low Ki67 index (30%), we diagnosed the case as atypical EP. The CHOP regimen was administered and complete remission achieved. This case indicated that EP should be considered as a differential diagnosis even when a tumor shows large cell morphology and is positive for CD3, CD56, and EBER1. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

19. Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.

Author

Kobayashi, Yukio, Munakata, Wataru, Ogura, Michinori, Uchida, Toshiki, Taniwaki, Masafumi, Kobayashi, Tsutomu, Shimada, Fumika, Yonemura, Masataka, Matsuoka, Fumiko, Tajima, Takeshi, Yakushijin, Kimikazu, and Minami, Hironobu

Abstract

The current therapy for high-risk myelodysplastic syndrome (MDS) involves repeated cycles of the DNA demethylating agent 5-azacitidine (5-Aza), but combination treatments have been proposed to improve patient outcomes. We performed a phase Ib study to investigate the safety and tolerability of 5-Aza (75 mg/m2) combined with the histone deacetylase inhibitor panobinostat (PAN) in adult Japanese patients with MDS or chronic myelomonocytic leukemia (CMML). Eleven patients were enrolled; five received 20 mg PAN + 5-Aza and six received 30 mg PAN + 5-Aza. All patients in the 20 mg PAN cohort had MDS, while two in the 30 mg PAN cohort had MDS and three had CMML. All patients experienced ≥1 adverse event (AE) related to the study treatment, and five discontinued the study treatment because of AEs. One patient in each group exhibited dose-limiting toxicities: lung infection (PAN 20 mg + 5-Aza) and cellulitis (PAN 30 mg + 5-Aza). PAN exposure increased with ascending doses, and combination therapy did not affect PAN plasma trough concentrations. In summary, 20 or 30 mg PAN combined with 5-Aza was safe and tolerable in adult Japanese patients with CMML or MDS. Study registration ClinicalTrials.gov Identifier: NCT01613976. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results